Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris businesswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesswire.com Daily Mail and Mail on Sunday newspapers.
NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN : FR0011341205 – the ‘‘
Company’’), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the pricing of its initial public offering on the Nasdaq Global Select Market by way of a capital increase of 7,300,000 new ordinary shares (the “
New Shares”), consisting of a public offering of 5,445,000 ordinary shares in the form of American Depositary Shares (“
ADSs”), each representing the right to receive one ordinary share, in the United States (the “
U.S. Offering”) and a concurrent offering of 1,855,000 ordinary shares in certain jurisdictions outside of the United States to certain investors (the “
NANOBIOTIX: Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
On December 1, 2020, the Nasdaq Stock Market filed a proposal with the Securities and Exchange Commission (SEC) to amend its listing standards to encourage greater board diversity and.